Inactive Instrument

Spark Therapeutics, Inc. Stock price

Equities

US84652J1034

Biotechnology & Medical Research

Dynamic Chart
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A CI
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022 CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform CI
Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease CI
Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer CI
Spark Therapeutics, Inc. Appoints Gallia Levy as Chief Medical Officer CI
More news
Managers TitleAgeSince
Chief Executive Officer - 17-04-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 50 17-09-24
Members of the board TitleAgeSince
Director/Board Member - 19-12-16
Director/Board Member - 19-12-16
More insiders
Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
More about the company
  1. Stock
  2. Equities
  3. Stock Spark Therapeutics, Inc. - Nasdaq